NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) Announces Collaboration to Evaluate Feasibility of Ultra Shear Technology Platform to Improve Effectiveness of SinuSys Lead Product Candidate
Pressure BioSciences (OTCQB: PBIO), today announced a collaboration with SinuSys Corporation aimed at evauating the potential for PBI’s innovative Ultra Shear Technology(TM) (“UST”) platform to strengthen the effectiveness of SinuSys Corp’s lead product candidate Restora. Depending on the outcome of the collaboration, SinuSys plans to license PBI’s UST platform for use with Restora on its path to FDA approval in a phase IIb clinical study later this year. PBIO is a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and platform technology services to the worldwide biotechnology, biotherapeutics and other industries. SinuSys Corporation is a medical device company focused on developing new therapies to improve the sinus health of patients. “Our patented UST platform is a unique breakthrough for nanoemulsification processing designed to resolve multiple substantive problems facing manufacturers of therapeutic drugs, nutraceuticals, and other products containing hydrophobic (water repelling) active ingredients that are at best poorly soluble in water,” said PBI chief science officer Dr. Alexander V. Lazarev in the press release. “Poor water solubility results in lower absorption rates and requires much higher loading of the active compounds into products to achieve targeted dosing and bioavailability of active ingredients for the patient. Unfortunately, poor water solubility also carries overdosing risks in conventional emulsions due to oil and water phases further separating and leading to non-uniform drug distribution. Scientific publications have demonstrated that hydrophobic active ingredients manufactured into high-quality nanoemulsions with droplet sizes of less than 100 nanometers can facilitate increased absorption and bioavailability while lowering doses and improving controlled release. This should result in better quality products and treatment experiences for the patient, with overall reduction in product costs.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Pressure BioSciences (OTCQB: PBIO), today announced a collaboration with SinuSys Corporation aimed at evauating the potential for PBI’s innovative Ultra Shear Technology(TM) (“UST”) platform to strengthen the effectiveness of SinuSys Corp’s lead product candidate Restora. Depending on the outcome of the collaboration, SinuSys plans to license PBI’s UST platform for use with Restora on its path to FDA approval in a phase IIb clinical study later this year. PBIO is a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and platform technology services to the worldwide biotechnology, biotherapeutics and other industries. SinuSys Corporation is a medical device company focused on developing new therapies to improve the sinus health of patients. “Our patented UST platform is a unique breakthrough for nanoemulsification processing designed to resolve multiple substantive problems facing manufacturers of therapeutic drugs, nutraceuticals, and other products containing hydrophobic (water repelling) active ingredients that are at best poorly soluble in water,” said PBI chief science officer Dr. Alexander V. Lazarev in the press release. “Poor water solubility results in lower absorption rates and requires much higher loading of the active compounds into products to achieve targeted dosing and bioavailability of active ingredients for the patient. Unfortunately, poor water solubility also carries overdosing risks in conventional emulsions due to oil and water phases further separating and leading to non-uniform drug distribution. Scientific publications have demonstrated that hydrophobic active ingredients manufactured into high-quality nanoemulsions with droplet sizes of less than 100 nanometers can facilitate increased absorption and bioavailability while lowering doses and improving controlled release. This should result in better quality products and treatment experiences for the patient, with overall reduction in product costs.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
